1. Home
  2. Useful resources
  3. Anticoagulation app
APP · INSTALL ON YOUR PHONE

Anticoagulation app

Stop and restart times for blocks and catheters. Works offline once opened.

Anticoagulation appStop and restart times for blocks and catheters. Works offline once opened.

Minimum time intervals from the joint ESAIC/ESRA guideline (2022) for neuraxial procedures and deep, non-compressible blocks. The same intervals apply to removing a catheter. "Low dose" means prophylactic and "high dose" means therapeutic. CrCl is creatinine clearance.

  • Superficial, compressible blocks: may be done while the patient takes anticoagulant or antiplatelet drugs, after weighing the risks; these intervals do not apply.
  • Deep, non-compressible blocks follow the same intervals as neuraxial procedures. The guideline's Table 2 sorts each block into deep or superficial. Depth from the skin is not the test: it is whether bleeding could be seen and compressed. Check Table 2, and local policy, for the planned block.
  • The same intervals apply to removing a catheter as to inserting a needle.
  • If the patient takes two drugs, use the longer interval.
  • Ultrasound guidance and bleeding-risk scores do not shorten the intervals.
  • After a bloody tap, consider delaying the next dose.
  • Reversal: prothrombin complex concentrate and vitamin K 10 mg for warfarin; idarucizumab for dabigatran; protamine for unfractionated heparin.

Antiplatelet drugs

DrugLast dose → needle or catheter removalNeedle or catheter removal → next dose
Aspirin, low dose (up to 200 mg/day)No interval needed, after a risk–benefit check. A single-shot spinal is preferred to an epidural.Routine time
Aspirin, high dose3 days (normal platelet count) to 7 days6 h
Clopidogrel5–7 days75 mg: without delay. 300 mg loading: 2 days. Not while a catheter is in place.
Prasugrel7 days24 h. Not while a catheter is in place.
Ticagrelor5 days24 h. Not while a catheter is in place.

Heparins and fondaparinux

DrugLast dose → needle or catheter removalNeedle or catheter removal → next dose
Unfractionated heparin, prophylactic SC4 hRoutine prophylaxis time
Unfractionated heparin, therapeuticIV: 6 h. SC: 12 h. And aPTT, anti-Xa or ACT in the normal range.Therapeutic dose only after the catheter is out; low-dose heparin meanwhile.
LMWH, prophylactic (e.g. enoxaparin 40 mg once daily)12 h (24 h if CrCl below 30 mL/min)Routine prophylaxis time
LMWH, therapeutic (e.g. enoxaparin 1 mg/kg twice daily)24 h (48 h if CrCl below 30 mL/min), or anti-Xa 0.1 IU/mL or lessTherapeutic dose only after the catheter is out; prophylactic LMWH meanwhile.
Fondaparinux 2.5 mg/day36 h (72 h if CrCl below 50 mL/min)Routine prophylaxis time
Fondaparinux, therapeuticNeuraxial not recommended. If unavoidable: about 4 days and calibrated anti-Xa 0.1 IU/mL or less.Low dose per routine

Vitamin K antagonists

DrugLast dose → needle or catheter removalNeedle or catheter removal → next dose
WarfarinAbout 5 days and INR in the normal range (INR below 1.5 may be acceptable after a risk–benefit check)Routine time. Not while a catheter is in place; use low-dose LMWH meanwhile.
AcenocoumarolAbout 3 days and normal INRAs warfarin
PhenprocoumonAbout 7 days and normal INRAs warfarin

Direct oral anticoagulants (low dose = prophylactic, high dose = therapeutic)

DrugLast dose → needle or catheter removalNeedle or catheter removal → next dose
DabigatranLow dose: 48 h. High dose: 72 h. If CrCl below 50 mL/min: proceed when dabigatran level is below 30 ng/mL or thrombin time is normal.Routine time; therapeutic doses only after the catheter is out.
RivaroxabanLow dose: 24 h (30 h if CrCl below 30). High dose: 72 h, or a drug level below 30 ng/mL if CrCl is below 30.Routine time; therapeutic doses only after the catheter is out.
ApixabanLow dose: 36 h. High dose: 72 h, or a drug level below 30 ng/mL.Routine time; therapeutic doses only after the catheter is out.
EdoxabanLow dose: 24 h (30 h if CrCl below 30). High dose: 72 h.Routine time; therapeutic doses only after the catheter is out.

Short-acting IV anticoagulants

DrugLast dose → needle or catheter removalNeedle or catheter removal → next dose
Argatroban, bivalirudinStop for 4–5 half-lives (argatroban about 4 h)Not stated

Source: Kietaibl S, Ferrandis R, Godier A, et al. Regional anaesthesia in patients on antithrombotic drugs: Joint ESAIC/ESRA guidelines. Eur J Anaesthesiol 2022;39:100–132. The full guideline is free on the ESRA guidelines page. Summarised by Nerve Blocks: check the original before acting, and always weigh the individual patient's bleeding and clotting risks.

The American Society of Regional Anesthesia and Pain Medicine (ASRA) guideline, fifth edition (2025): Regional anesthesia in the patient receiving antithrombotic or thrombolytic therapy. Timings apply to neuraxial and deep plexus or deep peripheral blocks, and to removing a catheter. "Low dose" means prophylactic and "high dose" means therapeutic. CrCl is creatinine clearance.

  • Deep plexus and deep peripheral blocks (for example lumbar plexus, paravertebral, infraclavicular, stellate ganglion) follow the same timings as neuraxial blocks.
  • Other peripheral blocks: decide on how easily the site can be compressed, how vascular it is and what bleeding there would mean.
  • "After" times run from needle placement or catheter removal, whichever is later. If a DOAC dose is given by mistake while a catheter is in, wait the full "before" time (or check a drug level) before removing it.
  • A bloody tap does not mean cancelling surgery, but discuss with the surgeon; for LMWH, delay the first dose by 24 h.
  • Do not use DOAC reversal drugs just to allow a routine block.

Antiplatelet drugs

DrugLast dose → block or catheter removalBlock or catheter removal → next dose
Aspirin and other NSAIDsNo interval neededNo specific timing
Clopidogrel5–7 daysStraight away if no loading dose; 6 h after catheter removal if a loading dose is given. A catheter may stay in 1–2 days if no loading dose.
Prasugrel7–10 daysStraight away if no loading dose; 6 h after catheter removal if a loading dose is given. No catheter while on prasugrel.
Ticagrelor5 daysStraight away if no loading dose; 6 h after catheter removal if a loading dose is given. No catheter while on ticagrelor.
Cilostazol2 days6 h after catheter removal (remove the catheter first)
Cangrelor (IV)3 h8 h after catheter removal (remove the catheter first)
Abciximab / eptifibatide, tirofibanUntil platelet function recovers: 24–48 h / 4–8 hContraindicated within 4 weeks of surgery

Unfractionated heparin

DrugLast dose → block or catheter removalBlock or catheter removal → next dose
Low dose SC (5000 U two or three times a day)4–6 h, or normal coagulation testsStraight away after catheter removal (remove 4–6 h after a dose). A catheter may stay in.
Higher dose SC (7500–10 000 U twice a day, up to 20 000 U/day)12 h and normal coagulation testsWeigh catheter risks case by case
Above 10 000 U a dose or above 20 000 U/day SC24 h and normal coagulation testsWeigh catheter risks case by case
IV infusion4–6 h and normal coagulation tests1 h after needle placement or catheter removal (remove 4–6 h after the last dose)

Low molecular weight heparin (LMWH)

DrugLast dose → block or catheter removalBlock or catheter removal → next dose
Low dose (prophylactic)12 h (check anti-Xa ≤0.1 IU/mL if sooner)Once daily: first dose 12 h or more after the block; catheter out 12 h after a dose, next dose 4 h later. Twice daily: first dose the next day, at least 12 h after; remove the catheter before starting, next dose 4 h after removal.
High dose (therapeutic)24 h (anti-Xa ≤0.1 IU/mL, especially if over 75 years or CrCl ≤30)24 h after the block, or 48–72 h after high-bleeding-risk surgery. Catheter out at least 4 h before the first dose.

Fondaparinux

DrugLast dose → block or catheter removalBlock or catheter removal → next dose
Low dose (2.5 mg/day)36 h (younger) to 42 h (elderly); 58 h if CrCl 30–50; avoid if CrCl below 30Catheter out at least 6 h before the first dose
High dose (5–10 mg/day)70 h (younger), 105 h (elderly); or calibrated anti-Xa ≤0.1 IU/mLCatheter out at least 6 h before the first dose

Warfarin

DrugLast dose → block or catheter removalBlock or catheter removal → next dose
Warfarin5 days and normal INRRemove a catheter when INR is below 1.5. Neurological checks for 48 h after removal.

Direct oral anticoagulants (low dose = prophylactic, high dose = therapeutic)

DrugLast dose → block or catheter removalBlock or catheter removal → next dose
ApixabanLow dose: 36 h. High dose: 72 h. Or drug level below 30 ng/mL (or anti-Xa ≤0.1 IU/mL).Low dose: 6 h. High dose: 24 h.
RivaroxabanLow dose: 24 h (30 h if CrCl below 30). High dose: 72 h. Or drug level below 30 ng/mL (or anti-Xa ≤0.1 IU/mL).Low dose: 6 h. High dose: 24 h.
EdoxabanHigh dose: 72 h, or drug level below 30 ng/mL (or anti-Xa ≤0.1 IU/mL). No approved low dose.24 h
DabigatranLow dose: 48 h. High dose: 72 h (120 h if CrCl 30–49). If CrCl below 30: only with a level below 30 ng/mL.Low dose: 6 h. High dose: 24 h.

Other drugs

DrugLast dose → block or catheter removalBlock or catheter removal → next dose
Argatroban, bivalirudin, desirudinNeuraxial techniques not advisedNot stated
Thrombolytics (alteplase etc.)At least 48 h, with normal clotting tests including fibrinogenAvoid thrombolytics for 10 days after puncture of a non-compressible vessel
Herbal medicinesNo need to stopNo specific timing

Sources: Kopp SL, Vandermeulen E, McBane RD, Perlas A, Leffert L, Horlocker T. Regional anesthesia in the patient receiving antithrombotic or thrombolytic therapy: ASRA Pain Medicine evidence-based guidelines (fifth edition). Reg Anesth Pain Med 2026;51:1233–61 (online 2025). doi:10.1136/rapm-2024-105766 Previous edition: Horlocker TT, Vandermeuelen E, Kopp SL, Gogarten W, Leffert LR, Benzon HT. Regional anesthesia in the patient receiving antithrombotic or thrombolytic therapy: ASRA evidence-based guidelines (fourth edition). Reg Anesth Pain Med 2018;43:263–309. Summarised by Nerve Blocks: check the original before acting, and always weigh the individual patient's bleeding and clotting risks.

Shown in English, exactly as published: the licence does not allow the guideline to be changed or translated.

The UK guideline from the Association of Anaesthetists of Great Britain and Ireland (AAGBI), the Obstetric Anaesthetists' Association and Regional Anaesthesia UK (2013): Regional anaesthesia and patients with abnormalities of coagulation. Table 1 of the UK guideline. Recommended minimum times are based in most circumstances on time to peak drug effect + (elimination half-life × 2), after which time < ¼ of the peak drug level will be present. For those drugs whose actions are unrelated to plasma levels, this calculation is not relevant. These recommendations relate primarily to neuraxial blocks and to patients with normal renal function except where indicated.

Heparins

DrugTime to peak effectElimination half-lifeAcceptable time after drug for block performanceAdministration of drug while spinal or epidural catheter in place1Acceptable time after block performance or catheter removal for next drug dose
UFH sc prophylaxis< 30 min1–2 h4 h or normal APTTRCaution1 h
UFH iv treatment< 5 min1–2 h4 h or normal APTTRCaution24 h
LMWH sc prophylaxis3–4 h3–7 h12 hCaution34 h3
LMWH sc treatment3–4 h3–7 h24 hNot recommended4 h4

Heparin alternatives

DrugTime to peak effectElimination half-lifeAcceptable time after drug for block performanceAdministration of drug while spinal or epidural catheter in place1Acceptable time after block performance or catheter removal for next drug dose
Danaparoid prophylaxis4–5 h24 hAvoid (consider anti-Xa levels)Not recommended6 h
Danaparoid treatment4–5 h24 hAvoid (consider anti-Xa levels)Not recommended6 h
Bivalirudin5 min25 min10 h or normal APTTRNot recommended6 h
Argatroban< 30 min30–35 min4 h or normal APTTRNot recommended6 h
Fondaparinux prophylaxis51–2 h17–20 h36–42 h (consider anti-Xa levels)Not recommended6–12 h
Fondaparinux treatment51–2 h17–20 hAvoid (consider anti-Xa levels)Not recommended12 h

Antiplatelet drugs

DrugTime to peak effectElimination half-lifeAcceptable time after drug for block performanceAdministration of drug while spinal or epidural catheter in place1Acceptable time after block performance or catheter removal for next drug dose
NSAIDs1–12 h1–12 hNo additional precautionsNo additional precautionsNo additional precautions
Aspirin12–24 hNot relevant; irreversible effectNo additional precautionsNo additional precautionsNo additional precautions
Clopidogrel12–24 hNot relevant; irreversible effect7 daysNot recommended6 h
Prasugrel15–30 minNot relevant; irreversible effect7 daysNot recommended6 h
Ticagrelor2 h8–12 h5 daysNot recommended6 h
Tirofiban< 5 min4–8 h68 hNot recommended6 h
Eptifibatide< 5 min4–8 h68 hNot recommended6 h
Abciximab< 5 min24–48 h648 hNot recommended6 h
Dipyridamole75 min10 hNo additional precautionsNo additional precautions6 h

Oral anticoagulants

DrugTime to peak effectElimination half-lifeAcceptable time after drug for block performanceAdministration of drug while spinal or epidural catheter in place1Acceptable time after block performance or catheter removal for next drug dose
Warfarin3–5 days4–5 daysINR ≤ 1.4Not recommendedAfter catheter removal
Rivaroxaban prophylaxis5 (CrCl > 30 ml.min−1)3 h7–9 h18 hNot recommended6 h
Rivaroxaban treatment5 (CrCl > 30 ml.min−1)3 h7–11 h48 hNot recommended6 h
Dabigatran prophylaxis or treatment7 (CrCl > 80 ml.min−1)0.5–2.0 h12–17 h48 hNot recommended6 h
Dabigatran (CrCl 50–80 ml.min−1)0.5–2.0 h15 h72 hNot recommended6 h
Dabigatran (CrCl 30–50 ml.min−1)0.5–2.0 h18 h96 hNot recommended6 h
Apixaban prophylaxis3–4 h12 h24–48 hNot recommended6 h

Thrombolytic drugs

DrugTime to peak effectElimination half-lifeAcceptable time after drug for block performanceAdministration of drug while spinal or epidural catheter in place1Acceptable time after block performance or catheter removal for next drug dose
Alteplase, anistreplase, reteplase, streptokinase< 5 min4–24 min10 daysNot recommended10 days

UFH, unfractionated heparin; sc, subcutaneous; APTTR, activated partial thromboplastin time ratio; iv, intravenous; LMWH, low molecular weight heparin; NSAIDs, non-steroidal anti-inflammatory drugs; INR, international normalised ratio; CrCl, creatinine clearance.

Notes to accompany Table 1

  1. The dangers associated with the administration of any drug that affects coagulation while a spinal or epidural catheter is in place should be considered carefully. There are limited data on the safety of the use of the newer drugs in this Table, and they are therefore not recommended until further data become available. The administration of those drugs whose entry in this column is marked as ‘caution’ may be acceptable, but the decision must be based on an evaluation of the risks and benefits of administration. If these drugs are given, the times identified in the column to the left (‘Acceptable time after drug for block performance’) should be used as a guide to the minimum time that should be allowed between drug administration and catheter removal.
  2. It is common for intravenous unfractionated heparin to be given a short time after spinal blockade or insertion of an epidural catheter during vascular and cardiac surgery. Local clinical governance guidelines should be followed and a high index of suspicion should be maintained if any signs attributable to vertebral canal haematoma develop.
  3. Low molecular weight heparins are commonly given in prophylactic doses twice daily after surgery, but many clinicians recommend that only one dose be given in the first 24 h after neuraxial blockade has been performed.
  4. Consider increasing to 24 h if block performance is traumatic.
  5. Manufacturer recommends caution with use of neuraxial catheters.
  6. Time to normal platelet function rather than elimination half-life.
  7. Manufacturer recommends that neuraxial catheters are not used.

Table 2: relative risk related to neuraxial and peripheral nerve blocks in patients with abnormalities of coagulation

RiskBlock categoryExamples of blocks in category
Higher riskEpidural with catheter
Single-shot epidural
Spinal
Paravertebral blocksParavertebral block; Lumbar plexus block; Lumbar sympathectomy; Deep cervical plexus block
Deep blocksCoeliac plexus block; Stellate ganglion block; Proximal sciatic block (Labat, Raj, sub-gluteal); Obturator block; Infraclavicular brachial plexus block; Vertical infraclavicular block; Supraclavicular brachial plexus block
Superficial perivascular blocksPopliteal sciatic block; Femoral nerve block; Intercostal nerve blocks; Interscalene brachial plexus block; Axillary brachial plexus block
Fascial blocksIlio-inguinal block; Ilio-hypogastric block; Transversus abdominis plane block; Fascia lata block
Superficial blocksForearm nerve blocks; Saphenous nerve block at the knee; Nerve blocks at the ankle; Superficial cervical plexus block; Wrist block; Digital nerve block; Bier's block
Normal riskLocal infiltration

Source: Association of Anaesthetists of Great Britain and Ireland, Obstetric Anaesthetists' Association and Regional Anaesthesia UK. Regional anaesthesia and patients with abnormalities of coagulation. Anaesthesia 2013; 68: 966–72. Open access under the Creative Commons CC BY-NC-ND licence; Tables 1 and 2 are reproduced unchanged. Check the original before acting, and always weigh the individual patient's bleeding and clotting risks.